Amarin Corp Plc (AMRN)

[Ajax133]

chas: The oddity of Jellis is that the trial was never accepted
by FDA, It didn't comply with PH III protocol, enrollment criteria, etc, or the results using sub optimal dosing of EPA with a disproportional number of women. A point that disturbs me is that
registrational trials based on Sub Set analysis of prior trials have failed to hit endpoints or be approved the majority of the time. This goes back 20 years. I truly hope this isn't one of those results.